about
Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach.Observational study of upper gastrointestinal tract bleeding events in patients taking duloxetine and nonsteroidal anti-inflammatory drugs: a case-control analysis.Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trialDuloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial.Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorderDose response and atypical antipsychotics in schizophrenia.A wellness intervention program for patients with mental illness: self-reported outcomes.Assessment of falls in older patients treated with duloxetine: a secondary analysis of a 24-week randomized, placebo-controlled trialThe risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials.Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.Onset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trials.CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial.What makes patients with fibromyalgia feel better? Correlations between Patient Global Impression of Improvement and changes in clinical symptoms and function: a pooled analysis of 4 randomized placebo-controlled trials of duloxetine.Evidence that ecdysteroids and methyl farnesoate control allometric growth and differentiation in a crustacean.Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.The effect of juvenile hormone III, methyl farnesoate, and methoprene on Na/K-ATPase activity in larvae of the brine shrimp, Artemia.The effect of duloxetine treatment on cognition in patients with fibromyalgia.Methyl farnesoate controls adult male morphogenesis in the crayfish, Procambarus clarkii.Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments.Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium.Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials.Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances.Early predictors of substantial weight gain in bipolar patients treated with olanzapine.Wellness intervention for patients with serious and persistent mental illness.Association of candidate gene polymorphisms with diastolic blood pressure change in patients treated with duloxetine.Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.A provisional screening instrument for four common mental disorders in adult primary care patients.Stimulation of ovarian maturation in the crayfish Procambarus clarkii by methyl farnesoate.PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients.Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis.Clinical relevance of depressive symptom improvement in bipolar I depressed patients.Methyl Farnesoate Levels in Male Spider Crabs Exhibiting Active Reproductive Behavior
P50
Q33355808-D3B5A4A7-7A99-41C0-AE4E-8F726865D7A3Q34462222-F88454D2-D172-4426-8EDB-ABF9D61E8F2AQ34853281-1D6E68B9-2BB2-42FC-8A88-13737D33D6F6Q35080568-FCE83421-7C17-48A3-9BCD-FCD555E03E34Q35557889-F8554914-2E82-44C2-991B-AA23CB83BF75Q35616778-C924CA72-F60A-4814-9378-038A8772C1B5Q35820327-372450DC-E2D9-4772-8F1A-24C74E041067Q36859550-A439BA41-BC6A-4250-961C-72208BCE33CDQ36866779-C998950F-2642-40B3-9C25-AE64CF0DE495Q37360532-195FB37B-3D62-4AFA-BC8F-5D996199FAE4Q37429717-3908D3E0-5D6B-4EE9-A684-1472721C8DC9Q38412823-D4E559B8-2F42-4D26-B6F5-EFDB177DC35CQ38434074-98E54CC2-7FE4-44A3-AF48-924107CEE2C4Q41005811-A47FEB93-9010-44CF-9B4C-0B30372A09FEQ42906475-7BDC14DB-2B70-4547-AC75-43E3CB830C54Q43260561-4086293F-1F4C-4D5F-8243-C843A3083483Q43832271-38249B89-93C1-4334-BC82-A46DCDD5B367Q44893030-A9A069B0-C07D-4F8A-ACD1-E9152D4CA6C0Q45241996-AB55C496-6623-4672-9387-9C13272F92CDQ45242001-22442B01-4EB6-4597-9955-ADDA5BC3F3A2Q45260010-2F478E61-027D-4C5D-A498-28A6677A1A6BQ45752307-752BD5AD-BFF4-47B0-B75C-8EBC315E4B1EQ46487257-2B25608B-6ECE-442F-AF0A-0A959B1CE2F5Q46596863-A92559FA-C440-49B6-B339-4EA1ADCA8101Q46763231-7A554147-FE0A-49F0-AAA6-2F9C4223D792Q46775465-7411E65D-0D1C-4F6E-982C-A8671075E3FBQ46837419-C25B0B8B-8567-4B3F-B08D-7775357AF264Q46890643-4D4E1E71-A56A-4A6E-8B3B-7CA56B667CC9Q46951970-0C90FF6B-4E24-4436-A472-CB42C746B96EQ47285056-DAF5C456-6D36-470D-B541-9C6A66A6DD47Q47337289-BD0523F1-17B6-4DB9-AA70-7535D0B9BEAEQ48518010-04431BDA-C7E0-493F-BEC8-5DC5929A28AAQ48558687-E1BC49C1-590F-4B3C-9C15-DF0D17419846Q48759820-48403221-96E0-46FA-8694-0462ECD9D751Q48916327-1D4898BB-8BFF-4339-8D0B-1629B50C5BA3Q48935200-47DBF5EF-31B4-4DE7-9DDE-E8597F76BA1BQ50787569-050C2F78-4117-427F-A1F8-78B8FA5D734EQ51900327-CCD81D5B-5898-45E5-829C-F8DCB30FB6F3Q51919912-26AD170B-F41C-48CE-9A92-6680D23EBC04Q60454958-69A8204A-D5B3-4943-BCCC-58E98D31ED29
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jonna Ahl
@ast
Jonna Ahl
@en
Jonna Ahl
@es
Jonna Ahl
@nl
Jonna Ahl
@sl
type
label
Jonna Ahl
@ast
Jonna Ahl
@en
Jonna Ahl
@es
Jonna Ahl
@nl
Jonna Ahl
@sl
prefLabel
Jonna Ahl
@ast
Jonna Ahl
@en
Jonna Ahl
@es
Jonna Ahl
@nl
Jonna Ahl
@sl
P106
P21
P31
P496
0000-0002-5661-6053
P569
2000-01-01T00:00:00Z